MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 64 filers reported holding MEREO BIOPHARMA GROUP PLC in Q3 2022. The put-call ratio across all filers is 1.76 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,984,795 | -2.3% | 11,616,120 | 0.0% | 0.56% | -14.3% |
| Q2 2023 | $15,333,278 | +109.2% | 11,616,120 | +12.1% | 0.66% | +245.3% |
| Q1 2023 | $7,327,810 | -5.7% | 10,366,120 | 0.0% | 0.19% | -44.0% |
| Q4 2022 | $7,774,590 | -12.9% | 10,366,120 | 0.0% | 0.34% | -24.7% |
| Q3 2022 | $8,926,000 | -52.4% | 10,366,120 | -38.1% | 0.45% | -54.4% |
| Q2 2022 | $18,767,000 | +11.7% | 16,756,120 | +11.7% | 0.99% | +62.4% |
| Q1 2022 | $16,800,000 | -29.6% | 15,000,000 | +0.6% | 0.61% | -46.2% |
| Q4 2021 | $23,863,000 | -12.7% | 14,914,447 | +32.0% | 1.13% | +47.5% |
| Q3 2021 | $27,346,000 | +52.4% | 11,300,000 | +99.6% | 0.76% | -32.2% |
| Q2 2021 | $17,944,000 | +82.7% | 5,660,608 | +94.2% | 1.13% | +96.7% |
| Q1 2021 | $9,823,000 | +48.0% | 2,914,861 | +57.3% | 0.57% | +17.9% |
| Q4 2020 | $6,635,000 | – | 1,853,417 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 1,854,278 | $6,638,000 | 3.61% |
| Asymmetry Capital Management, L.P. | 739,812 | $2,649,000 | 1.21% |
| Affinity Asset Advisors, LLC | 625,000 | $2,238,000 | 1.19% |
| Tri Locum Partners LP | 728,710 | $2,609,000 | 0.95% |
| Boxer Capital, LLC | 6,226,673 | $22,291,000 | 0.72% |
| DAFNA Capital Management LLC | 668,148 | $2,392,000 | 0.71% |
| Vivo Capital, LLC | 4,220,938 | $15,111,000 | 0.67% |
| Delphi Management Partners VIII, L.L.C. | 256,734 | $919,000 | 0.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 280,000 | $1,002,000 | 0.58% |
| Rubric Capital Management LP | 1,853,417 | $6,635,000 | 0.49% |